Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.
Journal
NEJM evidence
ISSN: 2766-5526
Titre abrégé: NEJM Evid
Pays: United States
ID NLM: 9918317485806676
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
medline:
1
7
2022
pubmed:
1
7
2022
entrez:
6
2
2024
Statut:
ppublish
Résumé
Fixed-Duration Ibrutinib-Venetoclax for CLLAmong 211 patients with CLL who received ibrutinib-venetoclax or chlorambucil-obinutuzumab, there were 22 and 67 progression-free survival (PFS) events at a median follow-up of 27.7 months, respectively. PFS was significantly longer (P<0.001), and improvement with ibrutinib-venetoclax was consistent across subgroups. Adverse events (grade ≥3) were similar in both arms.
Identifiants
pubmed: 38319255
doi: 10.1056/EVIDoa2200006
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM